Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Andrea Fanelli, Maria Cristina Sorella & Daniela Ghisi. (2018) Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain. Expert Review of Clinical Pharmacology 11:12, pages 1157-1162.
Read now
Read now
Lynn R. Webster, Eugene R. Viscusi, Colville Brown & Jeffrey M. Dayno. (2018) Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. Current Medical Research and Opinion 34:5, pages 893-901.
Read now
Read now
Lynn R. Webster, John Markman, Edward J. Cone & Gwendolyn Niebler. (2017) Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine 129:1, pages 102-110.
Read now
Read now
Benedikt Fischer, Chantal Burnett & Jürgen Rehm. (2015) Considerations towards a population health approach to reduce prescription opioid-related harms (with a primary focus on Canada). Drugs: Education, Prevention and Policy 22:1, pages 60-65.
Read now
Read now
Terri Morton, Kenneth Kostenbader, Jeannie Montgomery, Krishna Devarakonda, Thomas Barrett & Lynn Webster. (2014) Comparison of Subjective Effects of Extended-Release Versus Immediate-Release Oxycodone/Acetaminophen Tablets in Healthy Nondependent Recreational Users of Prescription Opioids: A Randomized Trial. Postgraduate Medicine 126:4, pages 20-32.
Read now
Read now
Caroline Victorri-Vigneau, Cedric Collin, Catherine Messina-Gourlot, Christel Raffournier, Michel Mallaret, Jérôme Besse, Marie-Anne Courne, Nathalie Richard, Véronique Sébille & Philippe Arnaud. (2014) Designing a tool allowing for a standardized assessment of resistance to drug diversion. Expert Opinion on Drug Delivery 11:7, pages 995-1004.
Read now
Read now
Michael J Brennan. (2013) Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare 6, pages 265-280.
Read now
Read now
Jeffrey A. Gudin. (2013) Assessment of Extended-Release Opioid Analgesics for the Treatment of Chronic Pain. Journal of Pain & Palliative Care Pharmacotherapy 27:1, pages 49-61.
Read now
Read now
Bruce Nicholson. (2013) Primary Care Considerations of the Pharmacokinetics and Clinical Use of Extended-Release Opioids in Treating Patients with Chronic Noncancer Pain. Postgraduate Medicine 125:1, pages 115-127.
Read now
Read now
Kenneth Kirsh, John Peppin & John Coleman. (2012) Characterization of Prescription Opioid Abuse in the United States: Focus on Route of Administration. Journal of Pain & Palliative Care Pharmacotherapy 26:4, pages 348-361.
Read now
Read now
Steven Stanos. (2012) Continuing evolution of opioid use in primary care practice: implications of emerging technologies. Current Medical Research and Opinion 28:9, pages 1505-1516.
Read now
Read now
Howard S Smith. (2011) Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opinion on Pharmacotherapy 12:7, pages 1111-1125.
Read now
Read now
Bill H. McCarberg. (2011) Pain Management in Primary Care: Strategies to Mitigate Opioid Misuse, Abuse, and Diversion. Postgraduate Medicine 123:2, pages 119-130.
Read now
Read now
David B. Brushwood, Ben A. Rich, John J. Coleman, Jennifer Bolen & Winston Wong. (2010) Legal Liability Perspectives on Abuse-Deterrent Opioids in the Treatment of Chronic Pain. Journal of Pain & Palliative Care Pharmacotherapy 24:4, pages 333-348.
Read now
Read now
Articles from other publishers (32)
Abay Asfaw, Brian Quay, Tim Bushnell & Regina Pana-Cryan. (2022) Injuries That Happen at Work Lead to More Opioid Prescriptions and Higher Opioid Costs. Journal of Occupational & Environmental Medicine 64:12, pages e823-e832.
Crossref
Crossref
Junchuan Liu, Jun Di, Yanlong Zhang & Enzeng Xing. (2021) Oxycodone–paracetamol tablet exhibits increased analgesic efficacy for acute postoperative pain, higher satisfaction and comparable safety profiles compared with celecoxib in patients underwent arthroscopic knee surgery. Inflammopharmacology 29:4, pages 1091-1099.
Crossref
Crossref
Lynn R Webster, Matthew Iverson, Carmela Pantaleon, Michael D Smith, Eric R Kinzler & Stefan Aigner. (2019) A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. Pain Medicine 20:4, pages 747-757.
Crossref
Crossref
Travis C Mickle, Sven M Guenther, Andrew C Barrett, Kathryn Ann Roupe, Jing Zhou, Daniel Dickerson & Lynn R Webster. (2018) Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users. Pain Medicine 19:12, pages 2438-2449.
Crossref
Crossref
Eric R. Kinzler, Carmela Pantaleon & Stefan Aigner. (2018) Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. Clinical Therapeutics 40:8, pages 1357-1365.
Crossref
Crossref
Aaron J. Salwan, Nicholas E. Hagemeier & Sam Harirforoosh. (2018) Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?. Clinical Drug Investigation 38:7, pages 573-577.
Crossref
Crossref
Wei Lu, Shunbo Zhao, Meng Gong, Luning Sun & Li Ding. (2018) Simultaneous determination of acetaminophen and oxycodone in human plasma by LC–MS/MS and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis 8:3, pages 160-167.
Crossref
Crossref
Lynn R. Webster, Carmela Pantaleon, Matthew Iverson, Michael D. Smith, Eric R. Kinzler & Stefan Aigner. (2018) Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management 2018, pages 1-10.
Crossref
Crossref
Henry Bundy & Gilbert Quintero. (2017) From mundane medicines to euphorigenic drugs: How pharmaceutical pleasures are initiated, foregrounded, and made durable. International Journal of Drug Policy 49, pages 109-116.
Crossref
Crossref
Lynn R. Webster, Michael D. Smith, John Lawler, Karsten Lindhardt & Jeffrey M. Dayno. (2016) Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. Pain Medicine, pages pnw219.
Crossref
Crossref
Michael D. Smith, Lynn R. Webster, John Lawler, Karsten Lindhardt & Jeffrey M. Dayno. (2016) Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. Pain Medicine, pages pnw174.
Crossref
Crossref
Nicole Jedinger, Simone Schrank, Johannes M. Fischer, Karlheinz Breinhälter, Johannes Khinast & Eva Roblegg. (2015) Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating. AAPS PharmSciTech 17:1, pages 68-77.
Crossref
Crossref
Lynn R. Webster, Ernest A. Kopecky, Michael D. Smith & Alison B. Fleming. (2015) A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Medicine, pages pnv020.
Crossref
Crossref
Terri L. Morton, Krishna Devarakonda, Kenneth Kostenbader, Jeannie Montgomery, Thomas Barrett & Lynn Webster. (2015) Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs. Pain Medicine, pages n/a-n/a.
Crossref
Crossref
N. Jedinger, J. Khinast & E. Roblegg. (2014) The design of controlled-release formulations resistant to alcohol-induced dose dumping – A review. European Journal of Pharmaceutics and Biopharmaceutics 87:2, pages 217-226.
Crossref
Crossref
Steven D. Passik. (2014) Tamper-Resistant Opioid Formulations in the Treatment of Acute Pain. Advances in Therapy 31:3, pages 264-275.
Crossref
Crossref
Edward M Sellers, Peter J Perrino, Salvatore V Colucci & Stephen C Harris. (2013)
Attractiveness of reformulated OxyContin
®
tablets: assessing comparative preferences and tampering potential
. Journal of Psychopharmacology 27:9, pages 808-816.
Crossref
Crossref
Peter J. Perrino, Salvatore V. Colucci, Glen Apseloff & Stephen C. Harris. (2013) Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults. Clinical Drug Investigation 33:6, pages 441-449.
Crossref
Crossref
C. Herry, A. Monti, F. Vauzelle-Kervroedan, P. Oury & L. Michel. (2013) Reducing abuse of orally administered prescription opioids using formulation technologies. Journal of Drug Delivery Science and Technology 23:2, pages 103-110.
Crossref
Crossref
Joy C. MacDermid, Mary Law, Norman Buckley & Robert Brian Haynes. (2012) “Push” versus “Pull” for mobilizing pain evidence into practice across different health professions: A protocol for a randomized trial. Implementation Science 7:1.
Crossref
Crossref
Tammi Schaeffer. (2012) Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics. Journal of Medical Toxicology 8:4, pages 400-407.
Crossref
Crossref
Bernard Bannwarth. (2012) Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?. Drugs 72:13, pages 1713-1723.
Crossref
Crossref
Lynn R Webster. (2011) Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. Pain Management 1:5, pages 417-425.
Crossref
Crossref
Kenneth L. Kirsh & Scott M. Fishman. (2011) Multimodal Approaches to Optimize Outcomes of Chronic Opioid Therapy in the Management of Chronic Pain. Pain Medicine 12:suppl 1, pages S1-S11.
Crossref
Crossref
Franklin K Johnson, Sabrina Ciric, Sophie Boudriau, James C Kisicki & Joseph Stauffer. (2011) The Relative Bioavailability of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules (EMBEDA®) and an Extended Release Morphine Sulfate Capsule Formulation (KADIAN®) in Healthy Adults Under Fasting Conditions. American Journal of Therapeutics 18:1, pages 2-8.
Crossref
Crossref
Benedikt Fischer, Meagan Bibby & Martin Bouchard. (2010) The Global Diversion of Pharmaceutical Drugs
Non‐medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction 105:12, pages 2062-2070.
Crossref
Crossref
Robert B. Raffa & Joseph V. PergolizziJrJr. (2010) Opioid Formulations Designed to Resist/Deter Abuse. Drugs 70:13, pages 1657-1675.
Crossref
Crossref
Sean T. Duggan & Lesley J. Scott. (2010) Morphine/Naltrexone. CNS Drugs 24:6, pages 527-538.
Crossref
Crossref
Michael J. Brennan & Steven Stanos. (2010) Strategies to Optimize Pain Management With Opioids While Minimizing Risk of Abuse. PM&R 2:6, pages 544-558.
Crossref
Crossref
Howard Smith & Patricia Bruckenthal. (2010) Implications of Opioid Analgesia for Medically Complicated Patients. Drugs & Aging 27:5, pages 417-433.
Crossref
Crossref
John J. Coleman, Charles R. Schuster & Robert L. DuPont. (2012) Reducing the Abuse Potential of Controlled Substances. Pharmaceutical Medicine 24:1, pages 21-36.
Crossref
Crossref
Gary S. Nichol, Vlad K. Kumirov, Ruben Vardanyan & Victor J. Hruby. (2010) Proton sharing and transfer in some zwitterionic compounds based on 4-oxo-4-((1-phenethylpiperidin-4-yl)(phenyl)amino)alcanoic acids. CrystEngComm 12:11, pages 3651.
Crossref
Crossref